What Ascenion GmbH does

Ascenion GmbH is a privately held knowledge and technology transfer organization (TTO) for academic life science research, headquartered in Munich and operating as a subsidiary of the non-profit LifeScience-Stiftung. Founded in 2001, the company supports a network of leading German research institutes — including Helmholtz Munich, the Max Delbrück Center, the Helmholtz-Zentrum für Infektionsforschung (HZI), Charité Berlin, and Hannover Medical School (MHH) — by protecting intellectual property, developing projects toward commercial readiness, brokering license deals and research collaborations with industry, and coaching academic spin-offs from inception through financing.

The company's core technology asset is a curated portfolio of more than 700 licensable technologies and research materials spanning therapeutics and diagnostics, research tools and analytics, medical devices and software, and green and white biotech. Ascenion operates Europe's leading life science partnering conference (BioVaria, launched 2008), which drew 320+ international participants in 2025 across 50+ research institutes, and administers the BMBF-funded GO-Bio initial program and the Life Science Digital Hub. Its proprietary platforms include the CARMA FUND (an early-stage life science investment vehicle initiated in 2022) and the Digital Technology Transfer Academy.

Ascenion generates revenue through four streams: licensing royalties and upfront/milestone payments on transferred IP, equity returns from its portfolio of spin-off holdings (held directly and via the LifeScience Foundation), fee-based consulting and advisory services to institutions, inventors, and industry clients, and program administration fees for BMBF-funded initiatives. Distribution is relationship-driven through six field offices co-located at partner research institutions across Germany (Munich, Berlin, Braunschweig, Hamburg, Hannover, Neuherberg), with international reach via BioVaria and partnerships including Oxford University Innovation and the Horizon 2020 commercialization consortium. Notable portfolio outcomes include exits of PhantomX (acquired by IBA, 2025), dentalXrai, and Tube Pharmaceuticals, alongside significant portfolio financings such as Cardior (€64M), T-knife ($110M), Aignostics ($34M Series B), and HepaRegeniX (€21.5M).

Name

Ascenion GmbH

Legal name

Ascenion GmbH

Website

https://ascenion.de

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Ascenion GmbH is a Munich-based technology transfer organization that protects, develops, and commercializes intellectual property from German academic life science institutes. It manages 700+ technologies, supports spin-offs, and operates BioVaria, Europe's leading academic-industry partnering conference.

Ownership category

akta.pro rank

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing Royalties: Revenue generated from licensing academic technologies and intellectual property to industry partners, including upfront payments, milestone payments, and ongoing royalties
2. Equity Holdings in Spin-offs: Ascenion and its LifeScience Foundation hold equity stakes in portfolio companies, generating returns through exits and dilution events
3. Professional Services: Fee-based consulting and advisory services for institutions, inventors, and industry clients including training programs and workshops
4. GO-Bio initial Program Administration: Administration of BMBF-funded GO-Bio initial program providing funding and support for early-stage life science projects

Go-to-market motion1 record

Distribution channels4 records

Marketing channels10 records

Core offering

Ascenion is a knowledge and technology transfer organization for academic life science research. It protects, develops, licenses, and commercializes IP from partner research institutes, supports biotech spin-off creation and financing, and connects academic inventors with industry and investors.

Product overview

Ascenion GmbH is a knowledge and technology transfer company for academic Life Science research. It operates as a service-based organization rather than a software product company, offering a portfolio of interconnected services including IP portfolio management, technology transfer consulting, and start-up coaching. The company organizes BioVaria, Europe's leading life science partnering event, and manages the CARMA FUND investment vehicle for early-stage life science projects. Additional offerings include the GO-Bio initial funding program and Digital Technology Transfer Academy, which together provide comprehensive support from idea protection through to company formation and financing.

Differentiator

Problem solved

Functional benefit

Brands

• BioVaria: Europe's leading platform for marketing innovative therapeutic, diagnostic and technological approaches emanating from academic research. Launched by Ascenion in 2008.
• CARMA FUND
• GO-Bio initial
• Life Science Digital Hub

Products and services

• BioVaria Europe's leading partnering platform and annual conference for marketing innovative therapeutic, diagnostic and technological approaches from academic research, connecting academic inventors with industry decision-makers and investors.
• CARMA FUND Early-stage investment fund for life science projects and start-ups, initiated by Ascenion, that co-invests in portfolio companies from partner institutes.
• GO-Bio initial BMBF-funded program providing early-stage funding and support for life science projects, including webinars and training workshops, administered by Ascenion.
• Digital Technology Transfer Academy Digital training platform offering webinars and workshops on technology transfer, business planning, and start-up development for life science researchers and entrepreneurs.
• IP Portfolio Management Services Services for protecting ideas and managing IP portfolios, including patent filing, licensing, and commercialization strategies for institutes, inventors and founders.
• Technology Transfer Consulting Advisory services for project development, market positioning, and commercialization of academic research technologies for industry and investors.
• Start-up Coaching Comprehensive support for founding and financing life science spin-offs, including business plan development and investor matching.
• Technology Offers Portfolio Online searchable portfolio of over 700 technologies and research materials across four categories: Therapeutics & Diagnostics, Research Materials Tools & Analytics, Medical Devices Software & Equipment, and Green & White Biotech.
• Life Science Digital Hub BMBF-funded digital platform providing resources, roadmaps, and workshops for scientists on business planning and founding start-ups.

Quantifiable outcome

• Multiple successful exits including dentalXrai, Tube Pharmaceuticals, and PhantomX acquisitions
• +5 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered major, core and minor.

• Horizon 2020 Consortium Partners (VIS, Karolinska Institutet, LifeArc)majorStrategic or Co-development Partner · 1 January 2017Consortium partnership since 2017 for promoting commercialization of EU-financed research projects. Ascenion and three other KTT organizations evaluate commercial potential of Horizon 2020-supported research.
• LifeScience-StiftungcoreStrategic or Co-development PartnerParent organization and founding entity of Ascenion; holds equity in portfolio companies and shapes technology transfer strategy. The foundation establishes framework conditions for spin-off equity participation.
• ASTP (Association of European Science and Technology Transfer Professionals)majorStrategic or Co-development PartnerProfessional technology transfer association where Ascenion contributed to launching RTTP (Registered Technology Transfer Professional) accreditation for promoting professional credibility and standards.
• TransferAllianzmajorStrategic or Co-development PartnerGerman association for knowledge and technology transfer representing TTOs of around 100 scientific institutions. Ascenion employees participate in expert panels, design professional development courses, and support lobbying activities.
• German Spin-off Framework PartnersmajorStrategic or Co-development PartnerAscenion supports the German Spin-off Framework launched by leading research institutions, technology transfer offices, and VC investors to enhance research-based spin-offs.
• Helmholtz Munich (HMGU)coreStrategic or Co-development PartnerMajor partner institute where Ascenion has staff located on-site. Secured exclusive license agreement with Champalimaud Foundation for chimeric co-stimulatory receptor technologies.
• Max Delbrück Center (MDC)coreStrategic or Co-development PartnerKey partner institute in Berlin; SB100X transposase licensed to Ensoma; exclusive IP license with Circular Genomics for Alzheimer's diagnostics; spin-offs include Captain T Cell and T-knife.
• Helmholtz-Zentrum für Infektionsforschung (HZI)coreStrategic or Co-development PartnerPartner institute in Braunschweig; multiple projects received innovation awards in 2026; spin-offs include LEOPARD Biosciences, Myxobiotics, Citrapeutics.
• Charité BerlincoreStrategic or Co-development PartnerMajor university medical center partner in Berlin; supported spin-offs including dentalXrai (acquired), PhantomX (acquired by IBA), Lucid Genomics, dotbase.
• Hannover Medical School (MHH)coreStrategic or Co-development PartnerPartner institute in Hannover; supported RNA Healer project which received IBT Lower Saxony funding of nearly EUR 2.5 million.
• Oxford University InnovationmajorStrategic or Co-development PartnerJoint webinar series presenting top licensable projects in gene and cell therapy from both organizations' portfolios.
• Medical University Innsbruck (MUI)minorStrategic or Co-development PartnerInternational partner institute in Austria; supported Diffratec Optics spin-off commercializing diffractive technologies.
• Leibniz-HKIminorStrategic or Co-development PartnerPartner institute; Biophelion spin-off from Leibniz-HKI and RWTH Aachen University developing fungal technology for circular economy in chemical industry.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• LifeArc: UK-based self-funded medical research charity that commercializes life science research, including spin-off formation and licensing; Ascenion has been a Horizon 2020 commercialization consortium partner with LifeArc since 2017.
• Max Planck Innovation: Technology transfer organization for the Max Planck Society in Germany; operates the same academic-to-industry IP transfer, licensing, and spin-off model that Ascenion runs for Helmholtz, Leibniz, and university partners.
• EMBLEM Technology Transfer: Technology transfer arm of the European Molecular Biology Laboratory (EMBL); commercializes life science research IP and supports spin-offs with a model and target customer base closely overlapping Ascenion's.
• Oxford University Innovation: The technology transfer office of the University of Oxford; runs a comparable model of academic life science IP management, spin-off formation, and licensing, and is an active joint webinar partner with Ascenion in the gene and cell therapy space.
• Cambridge Enterprise: University of Cambridge's technology transfer office; runs an analogous model of academic IP commercialization, spin-off creation, and seed investment that competes for the same European pharma and VC licensing demand.
• Fraunhofer Venture / Patent Center: Tech transfer arm of the Fraunhofer Society; Ascenion's CEO previously headed the Fraunhofer Patent Centre, and Fraunhofer offers highly comparable IP portfolio management, licensing, and spin-off coaching services to academic research in Germany.
• Karolinska Innovations: Tech transfer and commercialization arm of the Karolinska Institutet in Sweden; Ascenion's Horizon 2020 consortium partner and a direct competitor for European life science spin-off formation and licensing deals.

Regional players

• BioGenerator: US-based (St. Louis) non-profit that supports life science start-ups through gap funding and incubation from academic research; comparable mission and equity-based funding model but operates primarily in a different geography than Ascenion's European focus.

Broad incumbents

• IP Group plc: UK-listed IP commercialization company that builds and backs university spin-offs across multiple sectors including life sciences; competes with Ascenion for spin-off equity stakes and licensing opportunities from European academic research, but at much greater scale and across broader geographies.

Others

• Helmholtz Innovation: Transfer initiative of the Helmholtz Association of German research centres; Ascenion's primary partner institutions (Helmholtz Munich, HZI) sit within Helmholtz, making this an ecosystem counterpart rather than a direct competitor but still materially relevant for understanding the broader tech transfer landscape Ascenion operates within.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInde.linkedin.com/company/ascenion-gmbh
• Instagraminstagram.com/ascenion_de
• Xx.com/ascenion

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascenion GmbH